DF/HCC SPORE in Prostate Cancer

  • Beltran, Himisha (PI)
  • Balk, Steven P. (CoPI)
  • Brown, Myles A. (CoPI)
  • Freedman, Matthew L. (CoPI)
  • Garraway, Levi A. (CoPI)
  • Kantoff, Philip W. (CoPI)
  • Loda, Massimo (CoPI)
  • Freedman, Matthew M.L (CoPI)
  • Regan, Meredith M.M (CoPI)
  • Mucci, Lorelei (CoPI)
  • Brown, Myles M.A (CoPI)
  • Loda, Massimo M (CoPI)
  • Oh, William K. (CoPI)
  • Kantoff, Philip P.W (CoPI)
  • Regan, Meredith M. (CoPI)
  • Oh, William (CoPI)
  • Giovannucci, Edward (CoPI)
  • Golub, Todd R. (CoPI)
  • Loda, Massimo F. (CoPI)
  • Sellers, William R. (CoPI)
  • Spiegelman, Bruce M. (CoPI)

Project Details


This application represents a revised resubmission application for a Specialized Program of Research Excellence (SPORE) in Prostate Cancer from the Prostate Cancer Program of Dana-Farber/Harvard Cancer Center (DF/HCC). The DF/HCC Prostate Cancer SPORE has been funded for two cycles since 2002. DF/HCC is comprised of the following institutions: Dana-Farber Cancer Institute; Harvard Medical School; Harvard School of Public Health; Beth Israel-Deaconess Medical Center; Brigham and Women's Hospital; Massachusetts General Hospital; and Children's Hospital of Boston. In addition to the institutions in the DF/HCC, the Broad Institute and Massachusetts Institute of Technology are collaborating institutions in this grant. The DF/HCC Prostate Cancer SPORE has its administrative base at the DFCI. Dr. Philip Kantoff, who has led the DF/HCC Prostate Cancer Program and SPORE since their inception, is joined by Co-Directors Dr. William Hahn, a laboratory scientist at DFCI, and Dr. Steven Balk, a laboratory scientist at BIDMC. Dr. Kantoff reports directly to Dr. Edward Benz, Director of DF/HCC and President of DFCI. The DF/HCC Prostate Cancer SPORE has a broad and deep talent base and there is extensive institutional commitment. We take advantage of a large patient population and cutting edge technologies that are available to us as part of DF/HCC. We propose 4 Projects which address critical problems in prostate cancer and have translational components including 1) understanding the mechanism by which obesity impacts prostate cancer mortality 2) dissecting the clinical heterogeneity of Gleason 7 prostate cancer 3) understanding the role that genomic change has on resistance to primary androgen deprivation therapy and on aggressive prostate cancer and finally 4) understanding the androgen receptor based mechanisms of resistance in castration resistant disease. The four projects are supported by three Cores - an Administrative Core, a Biostatistics and Computational Biology Core, and a Tissue and Pathology Core. We also have a highly successful Career Development Program that selects talented physician scientists and mentors them to independence as well as a Developmental Projects Program that generates new ideas for the SPORE in the future.
Effective start/end date19/09/0230/06/19


Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.